Mining Twitter Hashtags to Find Unknown Drug Issues
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
Previous studies have shown that Twitter can be mined for bad drug interactions, but the Vermont team advances this idea by focusing on the distinctive information contained in hashtags-like “#overprescribed,” “#kidneystoneprobs,” and “#skinswelling”-to find new associations. The overall goal of the project, supported by the National Science Foundation, was to discover is to discover any relationship between two drugs that is not known.
Using their new algorithm, the team has created a website that will allow an investigator to explore the connections between search terms (say "albuterol"), existing scientific studies indexed in PubMed-and Twitter hashtags associated with the terms and studies.
A report on how the algorithm works, and its preliminary discoveries, was published online, June 8, in the Journal of Biomedical Informatics.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
